Quoin is an emerging specialty pharmaceutical company dedicated to developing therapeutic products for the treatment of rare and orphan diseases for which no FDA-approved treatments currently exist. Quoin’s lead product, QRX003, is under development for the treatment of Netherton Syndrome, a rare hereditary skin disease. In addition to Netherton Syndrome, Quoin’s pipeline includes potential treatments for other rare diseases including Peeling skin syndrome, SAM Syndrome, Palmoplantar Keratoderma and Epidermolysis Bullosa.
Quoin and Cellect Biotechnology Ltd have entered into a merger agreement. Please refer to the Cellect announcement for further details.
Our website is being updated. Please check back soon.
For more information about Quoin, please contact firstname.lastname@example.org